Our portfolio

Arthrogen

Developing local gene therapy for chronic diseases, Arthrogen utilizes viral-mediated gene transfer to treat conditions like rheumatoid arthritis. Their approach focuses on intra-articular delivery of therapeutic genes for sustained local treatment with minimal systemic side effects. Using adeno-associated virus (AAV) vectors, they are developing and validating new vectors and therapeutic genes.

Industry: Biotechnology, Gene Therapy, Rheumatology

Want to get in contact about Arthrogen?

We’re happy to connect. Reach out to our investment manager working with the team to learn more or explore potential opportunities.

Marc Roelofs

Life Science & Health

Our portfolio

Check out similar ventures

Advancing new therapeutics for Type 1 Diabetes and autoimmune diseases.
Advancing nanotechnology with sustainable, solvent-free nanoparticle synthesis.
Developing gene therapy solutions for heart rhythm disorders.
Pioneering cancer vaccines, DCPrime leverages its DCOne® dendritic cell technology to develop innovative immunotherapies.
Advancing new therapeutics for Type 1 Diabetes and autoimmune diseases.
Advancing nanotechnology with sustainable, solvent-free nanoparticle synthesis.
Developing gene therapy solutions for heart rhythm disorders.
Pioneering cancer vaccines, DCPrime leverages its DCOne® dendritic cell technology to develop innovative immunotherapies.